Amcor plc

- There is no explicit mention of plans for new fundraising through debt or equity in the provided pages. - The company focuses on deleveraging, targeting to reduce leverage to a 2.5 to 3x range by fiscal/calendar 2027. - They plan to use cash proceeds from divestitures (approximately $500 million from 6 noncore business sales) fully to reduce debt. - The company maintains a commitment to an investment-grade credit rating and a strong balance sheet. - No indications of issuing new equity or raising new debt were provided; emphasis is on free cash flow generation and debt reduction. - The company expects leverage at year-end around 3.4 to 3.5x but aims for improvement through synergy capture and cash flow improvement by calendar 2027.

- Fiscal 2026 capital spending is expected to be in the range of $850 million to $900 million, up compared to the prior year. - The company is initiating migration and consolidation of select corporate functions to a new U.S. headquarters in Miami, Florida starting in 2027. - Switzerland and Australia will remain important parts of the corporate footprint as key hubs. - No specific mention of other new strategic investments or projects, but focus continues on portfolio optimization, synergy capture, and operational execution.

- The core portfolio, including 6 focus categories (healthcare, beauty and wellness, proteins, liquids, foodservice, pet care), continues to outperform the total company with stronger EBIT margins and favorable mix. - Overall company volumes were down 1.5% in Q3 but showed improvement from prior quarters; core category volumes were flat or grew low to mid-single digits. - Emerging markets, especially Asia and Latin America, show mid-single-digit volume growth. - Growth synergies from the Amcor-Berry acquisition are progressing well, with $110 million annualized revenue won so far and expected to reach $280 million over 3 years. - Healthcare and nutrition categories, while currently weak, are expected to improve starting mid-2026. - Consumer demand is durable but cautious due to inflation; a low single-digit volume decline is anticipated in the second half of calendar year. - Synergy capture and new contract wins support revenue growth and EPS improvement going into fiscal and calendar 2027.

- Adjusted EPS for fiscal 2026 is expected in the range of $3.98 to $4.03 per share, representing roughly 12% growth at the midpoint, driven primarily by synergy realization. - Fourth quarter adjusted EPS growth is expected at approximately 20% year-over-year, reflecting near full impact of the Berry acquisition. - Synergy delivery is accelerating, with $77 million achieved in Q3 and $170 million for the first 9 months; expecting $270 million in synergies for fiscal 2026, ahead of the $260 million initial target. - Growth synergies are tracking well against a $280 million 3-year annualized revenue target; annualized revenue synergies now exceed $110 million, expected to ramp through calendar 2026. - EBIT margins improving in core portfolio, with synergies and favorable mix driving growth. - Commitment to deleveraging and strong free cash flow generation supports sustained earnings growth beyond fiscal 2026 into calendar fiscal 2027 and beyond.

The transcript on page 13 does not provide specific details on the current or expected order book or pending orders. However, relevant insights related to operational and market conditions include: - The company notes some weakness in fresh and frozen food segments within Nutrition but no overall Nutrition decline. - Customer and market trends show value-oriented essentials gaining traction. - Working capital investment remains elevated, with normalization expected leading to improved cash recovery in calendar 2027. - Supply chain normalization is a key factor influencing cash flow and leverage improvements. - Commitments to synergy capture and deleveraging are expected to favorably impact financials in fiscal and calendar 2027. - The company voices ongoing collaborative pricing discussions with customers to manage inflation impacts and supply continuity. No explicit statements about specific order book size or pending orders were mentioned.